ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oral Medications for Parkinson's Disease Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-2T17485
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Oral Medications for Parkinson s Disease Market Research Report 2024
BUY CHAPTERS

Global Oral Medications for Parkinson's Disease Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-2T17485
Report
November 2025
Pages:180
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AbbVie
Merck
Boehringer Ingelheim
GlaxoSmithKline PLC
Novartis Pharma
Supernus Pharmaceuticals
Bausch Health
Newron Pharmaceuticals
Teva Pharmaceutica
Glenmark Pharmaceuticals
Orion Pharma
Neurocrine Biosciences
Kyowa Kirin
UCB
Desitin Arzneimittel
Amneal Pharmaceuticals
Organon Pharma
F.Hoffmann-La Roche
Lundbeck
STADA

Oral Medications for Parkinson's Disease Market

The global Oral Medications for Parkinson's Disease market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Oral medications are a cornerstone of treatment for Parkinson's disease, a neurodegenerative disorder characterized by motor symptoms such as tremors, stiffness, and impaired movement. These medications are primarily designed to manage symptoms and improve quality of life by addressing the underlying dopamine deficiency in the brain. The most commonly prescribed drug is Levodopa, often combined with Carbidopa, which helps convert Levodopa into dopamine while minimizing side effects. Other oral medications include dopamine agonists that mimic dopamine's effects, MAO-B inhibitors that prevent the breakdown of brain dopamine, COMT inhibitors that prolong Levodopa's effects, and anticholinergics that help control tremors. Amantadine, an antiviral, is also used to manage symptoms and dyskinesia.
From a downstream perspective, Under 40 Years Old accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Oral Medications for Parkinson's Disease leading manufacturers including AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, Supernus Pharmaceuticals, Bausch Health, Newron Pharmaceuticals, Teva Pharmaceutica, Glenmark Pharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with AbbVie leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Oral Medications for Parkinson's Disease market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Oral Medications for Parkinson's Disease Market Report

Report Metric Details
Report Name Oral Medications for Parkinson's Disease Market
Segment by Type
  • L-Dopa Formulations
  • Dopamine Agonists
  • Mao-B Inhibitors
  • COMT Inhibitors
Segment by Application
  • Under 40 Years Old
  • 40-65 Years Old
  • Above 65 Years Old
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, Supernus Pharmaceuticals, Bausch Health, Newron Pharmaceuticals, Teva Pharmaceutica, Glenmark Pharmaceuticals, Orion Pharma, Neurocrine Biosciences, Kyowa Kirin, UCB, Desitin Arzneimittel, Amneal Pharmaceuticals, Organon Pharma, F.Hoffmann-La Roche, Lundbeck, Stada
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Oral Medications for Parkinson's Disease study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Oral Medications for Parkinson's Disease Market report?

Ans: The main players in the Oral Medications for Parkinson's Disease Market are AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, Supernus Pharmaceuticals, Bausch Health, Newron Pharmaceuticals, Teva Pharmaceutica, Glenmark Pharmaceuticals, Orion Pharma, Neurocrine Biosciences, Kyowa Kirin, UCB, Desitin Arzneimittel, Amneal Pharmaceuticals, Organon Pharma, F.Hoffmann-La Roche, Lundbeck, Stada

What are the Application segmentation covered in the Oral Medications for Parkinson's Disease Market report?

Ans: The Applications covered in the Oral Medications for Parkinson's Disease Market report are Under 40 Years Old, 40-65 Years Old, Above 65 Years Old

What are the Type segmentation covered in the Oral Medications for Parkinson's Disease Market report?

Ans: The Types covered in the Oral Medications for Parkinson's Disease Market report are L-Dopa Formulations, Dopamine Agonists, Mao-B Inhibitors, COMT Inhibitors

1 Study Coverage
1.1 Introduction to Oral Medications for Parkinson's Disease: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Oral Medications for Parkinson's Disease Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 L-Dopa Formulations
1.2.3 Dopamine Agonists
1.2.4 Mao-B Inhibitors
1.2.5 COMT Inhibitors
1.3 Market Segmentation by Application
1.3.1 Global Oral Medications for Parkinson's Disease Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Under 40 Years Old
1.3.3 40-65 Years Old
1.3.4 Above 65 Years Old
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oral Medications for Parkinson's Disease Revenue Estimates and Forecasts 2020-2031
2.2 Global Oral Medications for Parkinson's Disease Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Oral Medications for Parkinson's Disease Sales Estimates and Forecasts 2020-2031
2.4 Global Oral Medications for Parkinson's Disease Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Oral Medications for Parkinson's Disease Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Oral Medications for Parkinson's Disease Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 L-Dopa Formulations Market Size by Manufacturers
3.5.2 Dopamine Agonists Market Size by Manufacturers
3.5.3 Mao-B Inhibitors Market Size by Manufacturers
3.5.4 COMT Inhibitors Market Size by Manufacturers
3.6 Global Oral Medications for Parkinson's Disease Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Oral Medications for Parkinson's Disease Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Oral Medications for Parkinson's Disease Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Oral Medications for Parkinson's Disease Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Oral Medications for Parkinson's Disease Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Oral Medications for Parkinson's Disease Sales and Revenue by Type (2020-2031)
6.4 North America Oral Medications for Parkinson's Disease Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Oral Medications for Parkinson's Disease Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Oral Medications for Parkinson's Disease Sales and Revenue by Type (2020-2031)
7.4 Europe Oral Medications for Parkinson's Disease Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Oral Medications for Parkinson's Disease Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Oral Medications for Parkinson's Disease Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Oral Medications for Parkinson's Disease Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Oral Medications for Parkinson's Disease Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Oral Medications for Parkinson's Disease Sales and Revenue by Type (2020-2031)
9.4 Central and South America Oral Medications for Parkinson's Disease Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Oral Medications for Parkinson's Disease Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Oral Medications for Parkinson's Disease Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Oral Medications for Parkinson's Disease Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Oral Medications for Parkinson's Disease Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.1.4 AbbVie Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 AbbVie Oral Medications for Parkinson's Disease Sales by Product in 2024
11.1.6 AbbVie Oral Medications for Parkinson's Disease Sales by Application in 2024
11.1.7 AbbVie Oral Medications for Parkinson's Disease Sales by Geographic Area in 2024
11.1.8 AbbVie Oral Medications for Parkinson's Disease SWOT Analysis
11.1.9 AbbVie Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Business Overview
11.2.3 Merck Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.2.4 Merck Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Merck Oral Medications for Parkinson's Disease Sales by Product in 2024
11.2.6 Merck Oral Medications for Parkinson's Disease Sales by Application in 2024
11.2.7 Merck Oral Medications for Parkinson's Disease Sales by Geographic Area in 2024
11.2.8 Merck Oral Medications for Parkinson's Disease SWOT Analysis
11.2.9 Merck Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.3.4 Boehringer Ingelheim Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Boehringer Ingelheim Oral Medications for Parkinson's Disease Sales by Product in 2024
11.3.6 Boehringer Ingelheim Oral Medications for Parkinson's Disease Sales by Application in 2024
11.3.7 Boehringer Ingelheim Oral Medications for Parkinson's Disease Sales by Geographic Area in 2024
11.3.8 Boehringer Ingelheim Oral Medications for Parkinson's Disease SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Corporation Information
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.4.4 GlaxoSmithKline Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 GlaxoSmithKline Oral Medications for Parkinson's Disease Sales by Product in 2024
11.4.6 GlaxoSmithKline Oral Medications for Parkinson's Disease Sales by Application in 2024
11.4.7 GlaxoSmithKline Oral Medications for Parkinson's Disease Sales by Geographic Area in 2024
11.4.8 GlaxoSmithKline Oral Medications for Parkinson's Disease SWOT Analysis
11.4.9 GlaxoSmithKline Recent Developments
11.5 Novartis Pharma
11.5.1 Novartis Pharma Corporation Information
11.5.2 Novartis Pharma Business Overview
11.5.3 Novartis Pharma Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.5.4 Novartis Pharma Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Novartis Pharma Oral Medications for Parkinson's Disease Sales by Product in 2024
11.5.6 Novartis Pharma Oral Medications for Parkinson's Disease Sales by Application in 2024
11.5.7 Novartis Pharma Oral Medications for Parkinson's Disease Sales by Geographic Area in 2024
11.5.8 Novartis Pharma Oral Medications for Parkinson's Disease SWOT Analysis
11.5.9 Novartis Pharma Recent Developments
11.6 Supernus Pharmaceuticals
11.6.1 Supernus Pharmaceuticals Corporation Information
11.6.2 Supernus Pharmaceuticals Business Overview
11.6.3 Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.6.4 Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Supernus Pharmaceuticals Recent Developments
11.7 Bausch Health
11.7.1 Bausch Health Corporation Information
11.7.2 Bausch Health Business Overview
11.7.3 Bausch Health Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.7.4 Bausch Health Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Bausch Health Recent Developments
11.8 Newron Pharmaceuticals
11.8.1 Newron Pharmaceuticals Corporation Information
11.8.2 Newron Pharmaceuticals Business Overview
11.8.3 Newron Pharmaceuticals Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.8.4 Newron Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Newron Pharmaceuticals Recent Developments
11.9 Teva Pharmaceutica
11.9.1 Teva Pharmaceutica Corporation Information
11.9.2 Teva Pharmaceutica Business Overview
11.9.3 Teva Pharmaceutica Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.9.4 Teva Pharmaceutica Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Teva Pharmaceutica Recent Developments
11.10 Glenmark Pharmaceuticals
11.10.1 Glenmark Pharmaceuticals Corporation Information
11.10.2 Glenmark Pharmaceuticals Business Overview
11.10.3 Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.10.4 Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Glenmark Pharmaceuticals Recent Developments
11.11 Orion Pharma
11.11.1 Orion Pharma Corporation Information
11.11.2 Orion Pharma Business Overview
11.11.3 Orion Pharma Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.11.4 Orion Pharma Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Orion Pharma Recent Developments
11.12 Neurocrine Biosciences
11.12.1 Neurocrine Biosciences Corporation Information
11.12.2 Neurocrine Biosciences Business Overview
11.12.3 Neurocrine Biosciences Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.12.4 Neurocrine Biosciences Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Neurocrine Biosciences Recent Developments
11.13 Kyowa Kirin
11.13.1 Kyowa Kirin Corporation Information
11.13.2 Kyowa Kirin Business Overview
11.13.3 Kyowa Kirin Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.13.4 Kyowa Kirin Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Kyowa Kirin Recent Developments
11.14 UCB
11.14.1 UCB Corporation Information
11.14.2 UCB Business Overview
11.14.3 UCB Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.14.4 UCB Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 UCB Recent Developments
11.15 Desitin Arzneimittel
11.15.1 Desitin Arzneimittel Corporation Information
11.15.2 Desitin Arzneimittel Business Overview
11.15.3 Desitin Arzneimittel Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.15.4 Desitin Arzneimittel Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Desitin Arzneimittel Recent Developments
11.16 Amneal Pharmaceuticals
11.16.1 Amneal Pharmaceuticals Corporation Information
11.16.2 Amneal Pharmaceuticals Business Overview
11.16.3 Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.16.4 Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Amneal Pharmaceuticals Recent Developments
11.17 Organon Pharma
11.17.1 Organon Pharma Corporation Information
11.17.2 Organon Pharma Business Overview
11.17.3 Organon Pharma Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.17.4 Organon Pharma Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Organon Pharma Recent Developments
11.18 F.Hoffmann-La Roche
11.18.1 F.Hoffmann-La Roche Corporation Information
11.18.2 F.Hoffmann-La Roche Business Overview
11.18.3 F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.18.4 F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 F.Hoffmann-La Roche Recent Developments
11.19 Lundbeck
11.19.1 Lundbeck Corporation Information
11.19.2 Lundbeck Business Overview
11.19.3 Lundbeck Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.19.4 Lundbeck Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.19.5 Lundbeck Recent Developments
11.20 Stada
11.20.1 Stada Corporation Information
11.20.2 Stada Business Overview
11.20.3 Stada Oral Medications for Parkinson's Disease Product Models, Descriptions and Specifications
11.20.4 Stada Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2020-2025)
11.20.5 Stada Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Oral Medications for Parkinson's Disease Industry Chain
12.2 Oral Medications for Parkinson's Disease Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Oral Medications for Parkinson's Disease Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Oral Medications for Parkinson's Disease Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Oral Medications for Parkinson's Disease Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Oral Medications for Parkinson's Disease Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
AbbVie
Merck
Boehringer Ingelheim
GlaxoSmithKline PLC
Novartis Pharma
Supernus Pharmaceuticals
Bausch Health
Newron Pharmaceuticals
Teva Pharmaceutica
Glenmark Pharmaceuticals
Orion Pharma
Neurocrine Biosciences
Kyowa Kirin
UCB
Desitin Arzneimittel
Amneal Pharmaceuticals
Organon Pharma
F.Hoffmann-La Roche
Lundbeck
STADA
List of Tables
 Table 1. Global Oral Medications for Parkinson's Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Oral Medications for Parkinson's Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Oral Medications for Parkinson's Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Oral Medications for Parkinson's Disease Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Oral Medications for Parkinson's Disease Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Oral Medications for Parkinson's Disease Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Oral Medications for Parkinson's Disease Sales by Region (2020-2025) & (K Units)
 Table 8. Global Oral Medications for Parkinson's Disease Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Oral Medications for Parkinson's Disease Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Oral Medications for Parkinson's Disease Sales Share by Manufacturers (2020-2025)
 Table 12. Global Oral Medications for Parkinson's Disease Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Oral Medications for Parkinson's Disease Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Oral Medications for Parkinson's Disease by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Medications for Parkinson's Disease as of 2024)
 Table 16. Global Oral Medications for Parkinson's Disease Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Oral Medications for Parkinson's Disease Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Oral Medications for Parkinson's Disease Manufacturing Base and Headquarters
 Table 19. Global Oral Medications for Parkinson's Disease Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Oral Medications for Parkinson's Disease Sales by Type (2020-2025) & (K Units)
 Table 23. Global Oral Medications for Parkinson's Disease Sales by Type (2026-2031) & (K Units)
 Table 24. Global Oral Medications for Parkinson's Disease Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Oral Medications for Parkinson's Disease Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Oral Medications for Parkinson's Disease ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Oral Medications for Parkinson's Disease Sales by Application (2020-2025) & (K Units)
 Table 29. Global Oral Medications for Parkinson's Disease Sales by Application (2026-2031) & (K Units)
 Table 30. Oral Medications for Parkinson's Disease High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Oral Medications for Parkinson's Disease Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Oral Medications for Parkinson's Disease Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Oral Medications for Parkinson's Disease ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Oral Medications for Parkinson's Disease Growth Accelerators and Market Barriers
 Table 37. North America Oral Medications for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Oral Medications for Parkinson's Disease Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Oral Medications for Parkinson's Disease Growth Accelerators and Market Barriers
 Table 40. Europe Oral Medications for Parkinson's Disease Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Oral Medications for Parkinson's Disease Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Oral Medications for Parkinson's Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Oral Medications for Parkinson's Disease Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Oral Medications for Parkinson's Disease Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Oral Medications for Parkinson's Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Oral Medications for Parkinson's Disease Investment Opportunities and Key Challenges
 Table 47. Central and South America Oral Medications for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Oral Medications for Parkinson's Disease Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Oral Medications for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. AbbVie Corporation Information
 Table 51. AbbVie Description and Major Businesses
 Table 52. AbbVie Product Models, Descriptions and Specifications
 Table 53. AbbVie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. AbbVie Sales Value Proportion by Product in 2024
 Table 55. AbbVie Sales Value Proportion by Application in 2024
 Table 56. AbbVie Sales Value Proportion by Geographic Area in 2024
 Table 57. AbbVie Oral Medications for Parkinson's Disease SWOT Analysis
 Table 58. AbbVie Recent Developments
 Table 59. Merck Corporation Information
 Table 60. Merck Description and Major Businesses
 Table 61. Merck Product Models, Descriptions and Specifications
 Table 62. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Merck Sales Value Proportion by Product in 2024
 Table 64. Merck Sales Value Proportion by Application in 2024
 Table 65. Merck Sales Value Proportion by Geographic Area in 2024
 Table 66. Merck Oral Medications for Parkinson's Disease SWOT Analysis
 Table 67. Merck Recent Developments
 Table 68. Boehringer Ingelheim Corporation Information
 Table 69. Boehringer Ingelheim Description and Major Businesses
 Table 70. Boehringer Ingelheim Product Models, Descriptions and Specifications
 Table 71. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Boehringer Ingelheim Sales Value Proportion by Product in 2024
 Table 73. Boehringer Ingelheim Sales Value Proportion by Application in 2024
 Table 74. Boehringer Ingelheim Sales Value Proportion by Geographic Area in 2024
 Table 75. Boehringer Ingelheim Oral Medications for Parkinson's Disease SWOT Analysis
 Table 76. Boehringer Ingelheim Recent Developments
 Table 77. GlaxoSmithKline Corporation Information
 Table 78. GlaxoSmithKline Description and Major Businesses
 Table 79. GlaxoSmithKline Product Models, Descriptions and Specifications
 Table 80. GlaxoSmithKline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. GlaxoSmithKline Sales Value Proportion by Product in 2024
 Table 82. GlaxoSmithKline Sales Value Proportion by Application in 2024
 Table 83. GlaxoSmithKline Sales Value Proportion by Geographic Area in 2024
 Table 84. GlaxoSmithKline Oral Medications for Parkinson's Disease SWOT Analysis
 Table 85. GlaxoSmithKline Recent Developments
 Table 86. Novartis Pharma Corporation Information
 Table 87. Novartis Pharma Description and Major Businesses
 Table 88. Novartis Pharma Product Models, Descriptions and Specifications
 Table 89. Novartis Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Novartis Pharma Sales Value Proportion by Product in 2024
 Table 91. Novartis Pharma Sales Value Proportion by Application in 2024
 Table 92. Novartis Pharma Sales Value Proportion by Geographic Area in 2024
 Table 93. Novartis Pharma Oral Medications for Parkinson's Disease SWOT Analysis
 Table 94. Novartis Pharma Recent Developments
 Table 95. Supernus Pharmaceuticals Corporation Information
 Table 96. Supernus Pharmaceuticals Description and Major Businesses
 Table 97. Supernus Pharmaceuticals Product Models, Descriptions and Specifications
 Table 98. Supernus Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Supernus Pharmaceuticals Recent Developments
 Table 100. Bausch Health Corporation Information
 Table 101. Bausch Health Description and Major Businesses
 Table 102. Bausch Health Product Models, Descriptions and Specifications
 Table 103. Bausch Health Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Bausch Health Recent Developments
 Table 105. Newron Pharmaceuticals Corporation Information
 Table 106. Newron Pharmaceuticals Description and Major Businesses
 Table 107. Newron Pharmaceuticals Product Models, Descriptions and Specifications
 Table 108. Newron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Newron Pharmaceuticals Recent Developments
 Table 110. Teva Pharmaceutica Corporation Information
 Table 111. Teva Pharmaceutica Description and Major Businesses
 Table 112. Teva Pharmaceutica Product Models, Descriptions and Specifications
 Table 113. Teva Pharmaceutica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Teva Pharmaceutica Recent Developments
 Table 115. Glenmark Pharmaceuticals Corporation Information
 Table 116. Glenmark Pharmaceuticals Description and Major Businesses
 Table 117. Glenmark Pharmaceuticals Product Models, Descriptions and Specifications
 Table 118. Glenmark Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. Glenmark Pharmaceuticals Recent Developments
 Table 120. Orion Pharma Corporation Information
 Table 121. Orion Pharma Description and Major Businesses
 Table 122. Orion Pharma Product Models, Descriptions and Specifications
 Table 123. Orion Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 124. Orion Pharma Recent Developments
 Table 125. Neurocrine Biosciences Corporation Information
 Table 126. Neurocrine Biosciences Description and Major Businesses
 Table 127. Neurocrine Biosciences Product Models, Descriptions and Specifications
 Table 128. Neurocrine Biosciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 129. Neurocrine Biosciences Recent Developments
 Table 130. Kyowa Kirin Corporation Information
 Table 131. Kyowa Kirin Description and Major Businesses
 Table 132. Kyowa Kirin Product Models, Descriptions and Specifications
 Table 133. Kyowa Kirin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 134. Kyowa Kirin Recent Developments
 Table 135. UCB Corporation Information
 Table 136. UCB Description and Major Businesses
 Table 137. UCB Product Models, Descriptions and Specifications
 Table 138. UCB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 139. UCB Recent Developments
 Table 140. Desitin Arzneimittel Corporation Information
 Table 141. Desitin Arzneimittel Description and Major Businesses
 Table 142. Desitin Arzneimittel Product Models, Descriptions and Specifications
 Table 143. Desitin Arzneimittel Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 144. Desitin Arzneimittel Recent Developments
 Table 145. Amneal Pharmaceuticals Corporation Information
 Table 146. Amneal Pharmaceuticals Description and Major Businesses
 Table 147. Amneal Pharmaceuticals Product Models, Descriptions and Specifications
 Table 148. Amneal Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 149. Amneal Pharmaceuticals Recent Developments
 Table 150. Organon Pharma Corporation Information
 Table 151. Organon Pharma Description and Major Businesses
 Table 152. Organon Pharma Product Models, Descriptions and Specifications
 Table 153. Organon Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 154. Organon Pharma Recent Developments
 Table 155. F.Hoffmann-La Roche Corporation Information
 Table 156. F.Hoffmann-La Roche Description and Major Businesses
 Table 157. F.Hoffmann-La Roche Product Models, Descriptions and Specifications
 Table 158. F.Hoffmann-La Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 159. F.Hoffmann-La Roche Recent Developments
 Table 160. Lundbeck Corporation Information
 Table 161. Lundbeck Description and Major Businesses
 Table 162. Lundbeck Product Models, Descriptions and Specifications
 Table 163. Lundbeck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 164. Lundbeck Recent Developments
 Table 165. Stada Corporation Information
 Table 166. Stada Description and Major Businesses
 Table 167. Stada Product Models, Descriptions and Specifications
 Table 168. Stada Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 169. Stada Recent Developments
 Table 170. Key Raw Materials Distribution
 Table 171. Raw Materials Key Suppliers
 Table 172. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 173. Milestones in Production Technology Evolution
 Table 174. Distributors List
 Table 175. Market Trends and Market Evolution
 Table 176. Market Drivers and Opportunities
 Table 177. Market Challenges, Risks, and Restraints
 Table 178. Research Programs/Design for This Report
 Table 179. Key Data Information from Secondary Sources
 Table 180. Key Data Information from Primary Sources


List of Figures
 Figure 1. Oral Medications for Parkinson's Disease Product Picture
 Figure 2. Global Oral Medications for Parkinson's Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. L-Dopa Formulations Product Picture
 Figure 4. Dopamine Agonists Product Picture
 Figure 5. Mao-B Inhibitors Product Picture
 Figure 6. COMT Inhibitors Product Picture
 Figure 7. Global Oral Medications for Parkinson's Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Under 40 Years Old
 Figure 9. 40-65 Years Old
 Figure 10. Above 65 Years Old
 Figure 11. Oral Medications for Parkinson's Disease Report Years Considered
 Figure 12. Global Oral Medications for Parkinson's Disease Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 14. Global Oral Medications for Parkinson's Disease Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global Oral Medications for Parkinson's Disease Revenue Market Share by Region (2020-2031)
 Figure 16. Global Oral Medications for Parkinson's Disease Sales (2020-2031) & (K Units)
 Figure 17. Global Oral Medications for Parkinson's Disease Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 18. Global Oral Medications for Parkinson's Disease Sales Market Share by Region (2020-2031)
 Figure 19. Top 5 and Top 10 Manufacturers Oral Medications for Parkinson's Disease Sales Volume Market Share in 2024
 Figure 20. Global Oral Medications for Parkinson's Disease Revenue Market Share Ranking (2024)
 Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 22. L-Dopa Formulations Revenue Market Share by Manufacturer in 2024
 Figure 23. Dopamine Agonists Revenue Market Share by Manufacturer in 2024
 Figure 24. Mao-B Inhibitors Revenue Market Share by Manufacturer in 2024
 Figure 25. COMT Inhibitors Revenue Market Share by Manufacturer in 2024
 Figure 26. Global Oral Medications for Parkinson's Disease Sales Market Share by Type (2020-2031)
 Figure 27. Global Oral Medications for Parkinson's Disease Revenue Market Share by Type (2020-2031)
 Figure 28. Global Oral Medications for Parkinson's Disease Sales Market Share by Application (2020-2031)
 Figure 29. Global Oral Medications for Parkinson's Disease Revenue Market Share by Application (2020-2031)
 Figure 30. North America Oral Medications for Parkinson's Disease Sales YoY (2020-2031) & (K Units)
 Figure 31. North America Oral Medications for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. North America Top 5 Manufacturers Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) in 2024
 Figure 33. North America Oral Medications for Parkinson's Disease Sales Volume (K Units) by Type (2020- 2031)
 Figure 34. North America Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 35. North America Oral Medications for Parkinson's Disease Sales Volume (K Units) by Application (2020-2031)
 Figure 36. North America Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 37. US Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 38. Canada Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 39. Mexico Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 40. Europe Oral Medications for Parkinson's Disease Sales YoY (2020-2031) & (K Units)
 Figure 41. Europe Oral Medications for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
 Figure 42. Europe Top 5 Manufacturers Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) in 2024
 Figure 43. Europe Oral Medications for Parkinson's Disease Sales Volume (K Units) by Type (2020-2031)
 Figure 44. Europe Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 45. Europe Oral Medications for Parkinson's Disease Sales Volume (K Units) by Application (2020-2031)
 Figure 46. Europe Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 47. Germany Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 48. France Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 49. U.K. Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 50. Italy Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 51. Russia Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific Oral Medications for Parkinson's Disease Sales YoY (2020-2031) & (K Units)
 Figure 53. Asia-Pacific Oral Medications for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Asia-Pacific Top 8 Manufacturers Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) in 2024
 Figure 55. Asia-Pacific Oral Medications for Parkinson's Disease Sales Volume (K Units) by Type (2020- 2031)
 Figure 56. Asia-Pacific Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 57. Asia-Pacific Oral Medications for Parkinson's Disease Sales Volume (K Units) by Application (2020-2031)
 Figure 58. Asia-Pacific Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 59. Indonesia Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 60. Japan Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 61. South Korea Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 62. China Taiwan Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 63. India Oral Medications for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
 Figure 64. Central and South America Oral Medications for Parkinson's Disease Sales YoY (2020-2031) & (K Units)
 Figure 65. Central and South America Oral Medications for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
 Figure 66. Central and South America Top 5 Manufacturers Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) in 2024
 Figure 67. Central and South America Oral Medications for Parkinson's Disease Sales Volume (K Units) by Type (2021-2031)
 Figure 68. Central and South America Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 69. Central and South America Oral Medications for Parkinson's Disease Sales Volume (K Units) by Application (2020-2031)
 Figure 70. Central and South America Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 71. Brazil Oral Medications for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
 Figure 72. Argentina Oral Medications for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
 Figure 73. Middle East, and Africa Oral Medications for Parkinson's Disease Sales YoY (2020-2031) & (K Units)
 Figure 74. Middle East and Africa Oral Medications for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
 Figure 75. Middle East and Africa Top 5 Manufacturers Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) in 2024
 Figure 76. Middle East and Africa Oral Medications for Parkinson's Disease Sales Volume (K Units) by Type (2021-2031)
 Figure 77. South America Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 78. Middle East and Africa Oral Medications for Parkinson's Disease Sales Volume (K Units) by Application (2020-2031)
 Figure 79. Middle East and Africa Oral Medications for Parkinson's Disease Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 80. GCC Countries Oral Medications for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
 Figure 81. Turkey Oral Medications for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
 Figure 82. Egypt Oral Medications for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
 Figure 83. South Africa Oral Medications for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
 Figure 84. Oral Medications for Parkinson's Disease Industry Chain Mapping
 Figure 85. Regional Oral Medications for Parkinson's Disease Manufacturing Base Distribution (%)
 Figure 86. Global Oral Medications for Parkinson's Disease Production Market Share by Region (2020-2031)
 Figure 87. Oral Medications for Parkinson's Disease Production Process
 Figure 88. Regional Oral Medications for Parkinson's Disease Production Cost Structure
 Figure 89. Channels of Distribution (Direct Vs Distribution)
 Figure 90. Bottom-up and Top-down Approaches for This Report
 Figure 91. Data Triangulation
 Figure 92. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Oral Parkinson s Disease Medications Market Research Report 2024
Global Oral Antiparkinsonian Drugs Market Research Report 2024
Global Carbidopa Levodopa Tablets Market Research Report 2025
Global Levodopa Tablets Market Research Report 2024
Global Anti Parkinson s Disease Drugs Market Research Report 2024
Global Parkinsons Disease Drug Market Insights Forecast to 2030
Global Parkinson s Disease PD Drugs Market Research Report 2024
Global Compound Levodopa Market Research Report 2025
Global Anticholinergic Drugs For PD Market Research Report 2025
Global Parkinson s Disease Therapeutics Market Research Report 2025
Global Parkinson Disease Drug Market Insights Forecast to 2030
Global Modafinil Oral Drugs Market Research Report 2024
Global Carbidopa and Levodopa API Market Research Report 2025
Global Carbidopa and Levodopa Sustained release Tablets Market Research Report 2024
Global Oral Anorexiant Drug Market Research Report 2024
Global Dopamine Receptor Agonists For PD Market Research Report 2025
Global Dopamine Receptor Agonists Market Research Report 2025
Global Digoxin Oral Solution Market Research Report 2024
Oral Medicines for Diabetes Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Memantine Preparations Market Research Report 2024

RELATED REPORTS

Global Amyotrophic Lateral Sclerosis Gene Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4R20263
Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Online Speech Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-39V19943
Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Nerve Repair and Regeneration Devices Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-10C17235
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Neurological Disease Model Chip Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-7M17348
Thu Nov 06 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions